FLT3 and cancer: Most FLT3 inhibitors possess antitumor activity as they can block the activated STAT5 pathway in AML cells with FLT3-ITD, and combination approaches with quizartinib or midostaurin and other anti-cancer drugs were mainly studied in myeloid leukemia and not solid tumors [29].